Presenting Updates from Our Leading Portfolio of Epilepsy Programs
We are excited to highlight the latest across our precision epilepsy programs, including enrolling studies and positive topline data from the RADIANT study, showcasing best-in-disease efficacy for vormatrigine in patients with focal onset seizures.
Click below to learn more about our enrolling clinical trials
for children diagnosed with early-onset SCN2A or SCN8A DEE
To learn more, visit resiliencestudies.com/embold
for children and adults diagnosed with any DEE and related syndrome
To learn more, visit resiliencestudies.com/emerald
Praxis Presentations
| Platform Session – Drug Therapy | 15:15 – 16:15 | |||
|---|---|---|---|
| Presentation Number | Presentation Title | download talk | |
| Talk 4 Aud V (Pav1) |
Establishing the Predictive Validity of Preclinical Seizure Models in Generalized Epilepsies: An Extension of the Praxis Analysis of Concordance Framework |  |
|
| POSTER Presentations | 13:45 - 15:15 | |||
|---|---|---|---|
| Presentation Number | Presentation Title | download poster | |
| P196 (Pav 3) | Vormatrigine Rapidly Reduces Seizures in Adults with Treatment-Resistant Epilepsy: Results from the RADIANT Open Label Phase 2 Study | |
|
| P157 (Pav 3) | Relutrigine Demonstrates Robust Seizure Reduction and Seizure Freedom in DEEs: Results from the EMBOLD Study | |
|
| P158 (Pav 3) | Emergency Use Case of Relutrigine, a Functional State Sodium Channel Modulator, in an Infant with SCN2A-DEE and Refractory Status Epilepticus | |
P504 (Pav 4) | Complementary Antisense Oligonucleotide Treatment and Precision Sodium Channel Modulation for Early Onset SCN2A Developmental and Epileptic Encephalopathy: Emergency Use Cases in a Preterm Infant with Refractory Status Epilepticus | |
| P505 (Pav 4) | EMERALD: A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants with Developmental and Epileptic Encephalopathies | |
|
| P635 (Pav 5) | Epilepsy Monitoring of Prospective Seizure Observations with Electronic Records (EMPOWER): A Novel, Prospective, Large-scale, Observational Study Designed to Better Understand the Patient Journey | |
|
| YES Poster Tour (S2) | 14:00 – 14:30 | |||
|---|---|---|---|
| Presentation Number | Presentation Title | download poster | |
| 157 (Pav 3) | Relutrigine Demonstrates Robust Seizure Reduction and Seizure Freedom in DEEs: Results from the EMBOLD Study | |
|
| P249 (Pav 3) | Clinical Updates from the Elsunersen Emergency Use Program: A Novel ASO for Treatment of Early Onset SCN2A Developmental and Epileptic Encephalopathy | |
|
| Poster Presentations | 13:45 - 15:15 | |||
|---|---|---|---|
| Presentation Number | Presentation Title | download poster | |
| P202 (Pav 3) | Vormatrigine Demonstrates Potent Antiseizure Activity Across Three Acute Models with Highest Predictive Validity for Focal Onset Seizures | |
|
| P212 (Pav 3) | Preclinical Findings of Relutrigine, a Precision Sodium Channel Modulator, Point to Anticonvulsant Potential in Dravet Syndrome | |
|
| P225 (Pav 3) | POWER1 – A Double-Blind, Randomized, Multicenter Phase 2/3 Study Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Onset Seizures | |
|
| P248 (Pav 3) | Updates from the First-in-human Phase 1 Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Food Effect of Vormatrigine in Healthy Participants | |
|
| P249 (Pav 3) | Clinical Updates from the Elsunersen Emergency Use Program: A Novel ASO for Treatment of Early Onset SCN2A Developmental and Epileptic Encephalopathy | |
|
| YES Poster Tour (T2) | 14:00 – 14:30 | |||
|---|---|---|---|
| Presentation Number | Presentation Title | download poster | |
| P635 (Pav 5) | Epilepsy Monitoring of Prospective Seizure Observations with Electronic Records (EMPOWER): A Novel, Prospective, Large-scale, Observational Study Designed to Better Understand the Patient Journey | |
|
Meet Our Team
Stop by our booth and scientific exhibit to learn how Praxis is revolutionizing therapies in epilepsy, and don’t miss the chance to test your knowledge in the Exhibition Quiz!
Booth #435
Aug 30 – Sep 3, 2025
Lisbon, Portugal
Exhibition Quiz
Daily giveaways and a final prize to be drawn in our booth on Tuesday Sept 3